| Micro-channel |
 |
|
|
|
|
|
| |
| Treat bribe to upgrade! The medical enterprise should check and reverse to 2015 |
| |
| Author：中國銘鉉 企劃部 Release Time：2017-9-22 9:51:39 Number Browse：1274 |
| |
On September 22, the ministry of medicine issued a joint post to the central committee of the ministry of medicine, which launched the 2017 pharmaceutical purchase and marketing campaign, focusing on the special treatment of medical consumables. So far, a number of provinces and medical institutions have been deployed.
In jiangxi province, the latest news is that the province has upgraded its campaign, not only for medical supplies, but also for drugs and medical equipment. This round of wind movement through the end of the year, the whole pharmaceutical industry will avoid.
, according to jiangxi province industrial and commercial bureau of jiangxi province development planning commission, the food and drug administration, industrial and commercial bureau jointly issued "the province's medicine circulation field of commercial bribery rectification work action plan" (hereinafter referred to as the "scheme"), the decision from September to December, 2017 in the province unified to carry out the rectification of commercial bribery in pharmaceutical circulation field.
After watching the "solution" will find a clampdown in jiangxi province, is to take nine ministries of the two joint report of file content, and the state administration for industry and commerce of single check consumables bundling device file content, to mix together, also added some more detailed, more strict rules.
There are at least four highlights:
First, all pharmaceutical companies, including pharmaceuticals, medical consumables and medical equipment companies, are included in the target range. And it's not just the consumables that need to be targeted.
The plan stipulates that, by September 30, 2017, all pharmaceutical production, operating enterprises and medical institutions in jiangxi province will carry out self-examination of the contents of the special remediation.
Second, look for 2-3 years, not just new ones.
The plan stipulates that pharmaceutical companies should self-check the violation of business ethics and market rules of their own existence since 2015, and affect unfair trade practices of fair competition;
The medical establishment or relevant personnel should check the existence of the issue of commercial bribery of pharmaceutical enterprises.
Third, the principle of "confessing broad and resisting strict" is clarified.
The provisions of the plan may, in accordance with the law, be given light, mitigated or exempted from administrative penalties in accordance with the law in accordance with the law. If a person refuses to self-correct, conceals the problem or does what he or she does, it is found to be strictly handled.
Under this rule, the enterprise actively self-check, rectify the problem, obviously is a better choice.
Fourth, accept public reports.
In the scheme, public report the jiangxi provincial industrial and commercial bureau to report telephone and address, the city divided into districts and provinces county/city bureau of industrial and commercial bureau also released report telephone, accept the social from all walks of life to report pharmaceutical companies suspected of commercial bribery or medical institutions.
The industrial and commercial bureau/bureau is mainly to investigate the bribery and unfair competition of enterprises. Obviously, the regulation of jiangxi province is not only the medical institutions and doctors, but also the pharmaceutical enterprises.
The wind is stronger and stronger!
In addition, in jiangxi province's plan, the connotation of "bribery" is listed in more detail.
The following actions are not allowed to be focused on:
One is that the medicine production and management enterprises or medical institutions in the selling or buying of medicines, medical equipment, medical consumables process using money, valuables or other means to bribe the other unit or individual behavior.
Including "kickbacks" or under the guise of "cash", "promotion", "saving", "advertising", "KeYanFei", "system", "charge", "pay fee", "paid" and "commission", "sponsorship fees", such as name, or to reimburse all sorts of ways, such as to pay each other unit or individual property behavior;
Second, medicine production and management enterprises or marketing personnel in the process of clinical diagnosis and treatment to "order commission fees", "prescription fee", "new drug promotion fees", "clinical observation fees" and other name to pay medical institutions or the relevant personnel of cash and in-kind behavior, and to provide domestic and international tourism, examine nominal pay medical institution or the interests of the relevant personnel property other than the behavior;
Third, medical equipment (medical consumables) production, operating enterprises to lend to medical institutions leasing, donation, delivery of equipment and other forms, bundled sales of consumables and supporting equipment and other behaviors.
|
| |
Previous article：Periodontitis drug TOP10 products exposed to the local new drug in a strong stir
Next article：High value consumables intensive prices, a large number of enterprise products directly cut
|
| |
|
|
